Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2023-03-17 00:00:00 ET · period of report 2023-03-15 · accession 0001209191-23-019876 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-17 | 2023-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | — | +5,097 | 56.9K | +10% | — |
| D | 2023-03-17 | 2023-03-16 | TARS | Neervannan Seshadri | COO | S - Sale+OE | $13.43 | -357 | 56.6K | -0.6% | -$4,795 |
| D | 2023-03-17 | 2023-03-15 | TARS | Neervannan Seshadri | COO | M - OptEx | $0.00 | -5,097 | 15.3K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-15 | M | A | 5,097 | — | 56,934 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. |
| 2 | Common | Common Stock | 2023-03-16 | S | D | 357 | $13.43 | 56,577 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2023-03-15 | M | D | 5,097 | $0.00 | 15,291 | D | — · — to — | 5,097 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Company's common stock. (F5) RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |